抗GM-CSF抗体奥替利单抗对比沙利鲁单抗或安慰剂治疗对靶向治疗应答不佳的类风湿关节炎患者:III期随机试验(contRAst 3)
ContRAst 3是一项24周III期多中心随机对照试验,纳入549例对csDMARDs和生物制剂DMARDs和/或JAK抑制剂应答不佳的活动性类风湿关节炎患者。第12周时,奥替利单抗90 mg和150 mg组ACR20应答率分别为45%(p=0.2868)和51%(p=0.0596),与安慰剂组的38%相比无显著差异。奥替利单抗安全性可接受,但未达到主要终点,也未改善次要终点,且未证明非劣效于沙利鲁单抗。
要点
- 奥替利单抗90 mg和150 mg组第12周ACR20应答率分别为45%和51%,安慰剂组为38%,均无显著差异。
- 沙利鲁单抗在ACR20应答和次要终点上优于奥替利单抗。
- 各治疗组不良事件或严重不良事件发生率相似。
核心结论
- 奥替利单抗安全性可接受,但未达到ACR20主要终点,未改善次要终点,且未证明非劣效于沙利鲁单抗。
研究设计与样本
- ContRAst 3为24周III期多中心随机对照试验,共549例患者接受治疗。
- 患者接受皮下奥替利单抗(90/150 mg每周一次)、皮下沙利鲁单抗(200 mg每2周一次)或安慰剂12周,均联合csDMARDs。
- 安慰剂组患者在第12周转换为活性干预,治疗持续至第24周。
- 主要终点为第12周达到美国风湿病学会≥20%应答(ACR20)的患者比例。
主要发现
- 第12周ACR20应答率:奥替利单抗90 mg组45%(p=0.2868)、150 mg组51%(p=0.0596),安慰剂组38%,均无显著差异。
- 第12周奥替利单抗组在临床疾病活动指数、健康评估问卷-残疾指数、疼痛视觉模拟量表或慢性病治疗功能评估-疲劳评分方面与安慰剂组无显著差异。
- 沙利鲁单抗在ACR20应答和次要终点上优于奥替利单抗。
- 各治疗组不良事件或严重不良事件发生率相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the efficacy and safety of otilimab, an anti-granulocyte-macrophage colony-stimulating factor antibody, in patients with active rheumatoid arthritis and an inadequate response to conventional synthetic (cs) and biologic disease-modifying antirheumatic drugs (DMARDs) and/or Janus kinase inhibitors. METHODS: ContRAst 3 was a 24-week, phase III, multicentre, randomised controlled trial. Patients received subcutaneous otilimab (90/150 mg once weekly), subcutaneous sarilumab (200 mg every 2 weeks) or placebo for 12 weeks, in addition to csDMARDs. Patients receiving placebo were switched to active interventions at week 12 and treatment continued to week 24. The primary end point was the proportion of patients achieving an American College of Rheumatology ≥20% response (ACR20) at week 12. RESULTS: Overall, 549 patients received treatment. At week 12, there was no significant difference in the proportion of ACR20 responders with otilimab 90 mg and 150 mg versus placebo (45% (p=0.2868) and 51% (p=0.0596) vs 38%, respectively). There were no significant differences in Clinical Disease Activity Index, Health Assessment Questionnaire-Disability Index, pain Visual Analogue Scale or Functional Assessment of Chronic Illness Therapy-Fatigue scores with otilimab versus placebo at week 12. Sarilumab demonstrated superiority to otilimab in ACR20 response and secondary end points. The incidence of adverse or serious adverse events was similar across treatment groups. CONCLUSIONS: Otilimab demonstrated an acceptable safety profile but failed to achieve the primary end point of ACR20 and improve secondary end points versus placebo or demonstrate non-inferiority to sarilumab in this patient population. TRIAL REGISTRATION NUMBER: NCT04134728.
引用
- Taylor PC, Weinblatt ME, McInnes IB, et al. Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3). Ann Rheum Dis. 2023. PMID: 37696589. doi:10.1136/ard-2023-224449
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。